These findings underscore the therapeutic potential of combining AKT and Src inhibitors in PTEN-deficient cancers, addressing the limitations of AKT inhibition alone and offering a promising strategy to overcome resistance associated with PTEN loss. Here, AKT1 is linked to cancer.